Elisabeth Qvigstad

• Opsahl, Julia Onsrud; Moen, Gunn-Helen; Qvigstad, Elisabeth; Böttcher, Yvonne; Birkeland, Kåre I. & Sommer, Christine (2020). Epigenetic signatures associated with maternal body mass index or gestational weight gain: A systematic review. Journal of Developmental Origins of Health and Disease.  ISSN 2040-1744.  s 1- 11 . doi: 10.1017/S2040174420000811 Fulltekst i vitenarkiv.
• Arora, G. P.; Åkerlund, M.; Bruns, C; Moen, Gunn-Helen; Wasenius, N. S.; Sommer, Christine; Jenum, Anne Karen; Almgren, P; Thaman, R. G.; Orho-Melander, M; Eriksson, Johan Gunnar; Qvigstad, Elisabeth; Birkeland, Kåre I.; Berntorp, K; Vaag, Allan Arthur; Groop, L & Prasad, Rashmi B. (2019). Phenotypic and genotypic differences between Indian and Scandinavian women with gestational diabetes mellitus. Journal of Internal Medicine.  ISSN 0954-6820. . doi: 10.1111/joim.12903
• Lekva, Tove; Godang, Kristin; Michelsen, Annika; Qvigstad, Elisabeth; Normann, Kjersti Ringvoll; Norwitz, Errol R.; Aukrust, Pål; Henriksen, Tore; Bollerslev, Jens; Roland, Marie Cecilie & Ueland, Thor (2018). Prediction of gestational diabetes mellitus and pre-diabetes 5 years postpartum using 75 g oral glucose tolerance test at 14-16 Weeks' gestation. Scientific Reports.  ISSN 2045-2322.  8:13392, s 1- 9 . doi: 10.1038/s41598-018-31614-z Fulltekst i vitenarkiv.
• Moen, Gunn-Helen Øiseth; LeBlanc, Marissa; Sommer, Christine; Prasad, Rashmi B.; Lekva, Tove; Normann, Kjersti Ringvoll; Qvigstad, Elisabeth; Groop, Leif; Birkeland, Kåre I.; Evans, David M. & Frøslie, Kathrine Frey (2018). Genetic determinants of glucose levels in pregnancy: Genetic risk scores analysis and GWAS in the Norwegian STORK cohort. European Journal of Endocrinology.  ISSN 0804-4643.  179(6), s 363- 372 . doi: 10.1530/EJE-18-0478
• Moen, Gunn-Helen Øiseth; Qvigstad, Elisabeth; Birkeland, Kåre I.; Evans, David & Sommer, Christine (2018). Are serum concentrations of vitamin B-12 causally related to cardiometabolic risk factors and disease? A Mendelian randomization study. American Journal of Clinical Nutrition.  ISSN 0002-9165.  108(2), s 398- 404 . doi: 10.1093/ajcn/nqy101
• Moen, Gunn-Helen Øiseth; Sommer, Christine; Prasad, Rashmi B.; Sletner, Line; Groop, Leif; Qvigstad, Elisabeth & Birkeland, Kåre I. (2017). Epigenetic modifications and gestational diabetes: A Systematic review of published literature. European Journal of Endocrinology.  ISSN 0804-4643.  176(5), s R247- R267 . doi: 10.1530/EJE-16-1017
• Christensen, Jacob J.; Retterstøl, Kjetil; Godang, Kristin; Roland Paasche, Marie Cecilie; Qvigstad, Elisabeth; Bollerslev, Jens; Ueland, Thor; Henriksen, Tore & Holven, Kirsten Bjørklund (2016). LDL cholesterol in early pregnancy and offspring cardiovascular disease risk factors. Journal of Clinical Lipidology.  ISSN 1933-2874.  10(6), s 1369- 1378 . doi: 10.1016/j.jacl.2016.08.016 Vis sammendrag

  Background Vast amounts of data show associations between maternal obesity, dysglycemia, diabetes, and undernutrition during pregnancy and increased cardiovascular disease risk in offspring. However, elevated maternal LDL cholesterol (LDL-C) in pregnancy and offspring cardiovascular disease (CVD) risk has scarcely been studied. Objective Our objective was to investigate the associations between elevated maternal LDL-C in pregnancy and CVD risk factors in 6-to-13-year-old offspring. Methods We recruited 6-to-13-year-old children whose mothers attended a pregnancy cohort and who had high or low cholesterol in pregnancy, defined as LDL-C over the 90th percentile or below the 10th percentile within the pregnancy cohort, respectively. We measured CVD risk factors in the children in the 2 groups. Results Maternal plasma LDL-C at gestational week 14 to 16 was 4.0 and 1.4 mmol/L in the hypercholesterolemic (n = 27) and hypocholesterolemic (n = 34) groups, respectively (P < .001). Interestingly, offspring plasma LDL-C was 0.4 mmol/L higher in children whose mothers had hypercholesterolemia during pregnancy (P < .01). We found no difference in birthweight or any other clinical or biochemical CVD risk factors or dietary intake between the children at 6–13 years. Conclusions Women with elevated LDL-C during early pregnancy have offspring with higher LDL-C already at the age of 6–13 years. Unless cholesterol-reducing measures are successfully implemented, the affected children may be at increased cardiovascular risk.

• Frøslie, Kathrine Frey; Røislien, Jo; Qvigstad, Elisabeth; Godang, Kristin; Bollerslev, Jens; Henriksen, Tore & Veierød, Marit Bragelien (2014). Shape information in repeated glucose curves during pregnancy provided significant physiological information for neonatal outcomes. PLOS ONE.  ISSN 1932-6203.  9(3) . doi: 10.1371/journal.pone.0090798
• Godang, Kristin; Frøslie, Kathrine Frey; Henriksen, Tore; Qvigstad, Elisabeth & Bollerslev, Jens (2014). Seasonal variation in maternal and umbilical cord 25(OH) vitamin D and their associations with neonatal adiposity. European Journal of Endocrinology.  ISSN 0804-4643.  170(4), s 609- 617 . doi: 10.1530/EJE-13-0842
• Friis, Camilla Margrethe; Qvigstad, Elisabeth; Paasche, Marie Cecilie; Godang, Kristin; Voldner, Nanna; Bollerslev, Jens & Henriksen, Tore (2013). Newborn Body Fat: Associations with Maternal Metabolic State and Placental Size. PLOS ONE.  ISSN 1932-6203.  8(2) . doi: 10.1371/journal.pone.0057467
• Frøslie, Kathrine Frey; Røislien, Jo; Qvigstad, Elisabeth; Godang, Kristin; Bollerslev, Jens; Voldner, Nanna; Henriksen, Tore & Veierød, Marit Bragelien (2013). Shape information from glucose curves: Functional data analysis compared with traditional summary measures. BMC Medical Research Methodology.  ISSN 1471-2288.  13 . doi: 10.1186/1471-2288-13-6
• Frøslie, Kathrine Frey; Godang, Kristin; Bollerslev, Jens; Henriksen, Tore; Røislien, Jo; Veierød, Marit Bragelien & Qvigstad, Elisabeth (2011). Time-dependent trends in glucose values during long-term use of a glucose measurement system. Clinical Biochemistry.  ISSN 0009-9120.  44(17-18), s 1483- 1486 . doi: 10.1016/j.clinbiochem.2011.08.1150
• Frøslie, Kathrine Frey; Røislien, Jo; Laake, Petter; Henriksen, Tore; Qvigstad, Elisabeth & Veierød, Marit Bragelien (2010). Categorisation of continuous exposure variables revisited. A response to the Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) Study. BMC Medical Research Methodology.  ISSN 1471-2288.  10 . doi: 10.1186/1471-2288-10-103
• Godang, Kristin; Qvigstad, Elisabeth; Voldner, Nanna; Isaksen, Gunhild Aker; Frøslie, Kathrine Frey; Nøtthellen, Jacob A; Henriksen, Tore & Bollerslev, Jens (2010). Assessing Body Composition in Healthy Newborn Infants: Reliability of Dual-Energy X-Ray Absorptiometry. Journal of clinical densitometry.  ISSN 1094-6950.  13(2), s 151- 160 . doi: 10.1016/j.jocd.2010.01.121
• Voldner, Nanna; Qvigstad, Elisabeth; Frøslie, Kathrine Frey; Godang, Kristin; Henriksen, Tore & Bollerslev, Jens (2010). Increased risk of macrosomia among overweight women with high gestational rise in fasting glucose. Journal of Maternal-Fetal & Neonatal Medicine.  ISSN 1476-7058.  23(1), s 74- 81 . doi: 10.3109/14767050903121472
• Grill, Valdemar; Radtke, Maria; Qvigstad, Elisabeth; Kollind, Magnus & Bjorklund, A (2009). Beneficial effects of K-ATP channel openers in diabetes: an update on mechanisms and clinical experiences. Diabetes, obesity and metabolism.  ISSN 1462-8902.  11, s 143- 148 . doi: 10.1111/j.1463-1326.2009.01119.x
• Radtke, Maria; Kollind, Magnus; Qvigstad, Elisabeth & Grill, Valdemar (2007). Twelve weeks' treatment with diazoxide without insulin supplementation in Type 2 diabetes is feasible but does not improve insulin secretion. Diabetic Medicine.  ISSN 0742-3071.  24(2), s 172- 177 . doi: 10.1111/j.1464-5491.2006.02056.x
• Mostad, Ingrid Løvold; Qvigstad, Elisabeth; Bjerve, Kristian S & Grill, Valdemar (2004). Effects of a 3-day low-fat diet on metabolic control, insulin sensitivity, lipids and adipocyte hormones in Norwegian subjects with hypertriacylglycerolaemia and type 2 diabetes. Scandinavian Journal of Clinical and Laboratory Investigation.  ISSN 0036-5513.  64(6), s 565- 74
• Qvigstad, Elisabeth; Kollind, M & Grill, Valdemar (2004). Nine weeks of bedtime diazoxide is well tolerated and improves beta-cell function in subjects with Type 2 diabetes. Diabetic Medicine.  ISSN 0742-3071.  21(1), s 73- 76
• Qvigstad, Elisabeth; Kollind, Magnus & Grill, Valdemar (2004). Nine weeks of bedtime diazoxide is well tolerated and improves beta-cell function in subjects with Type 2 diabetes. Diabetic Medicine.  ISSN 0742-3071.  21, s 73- 76
• Qvigstad, Elisabeth; Grill, Valdemar; Bjerve, Kristian S & Mostad, Ingrid Løvold (2003). Acute lowering of fatty acids improves insulin secretion in a subset of type II diabetes subjects. American Journal of Physiology. Endocrinology and Metabolism.  ISSN 0193-1849.  284, s E129- E137 Vis sammendrag

  We tested the effects of acute perturbations of elevated fatty acids (FA) on insulin secretion in type II diabetes. Twenty-one type II diabetes subjects with hypertriglyceridemia (triacylglycerol > 2.2mmol/l) and ten age-matched non-diabetic subjects participated. Glucose-stimulated insulin secretion was monitored during hyperglycemic clamps for 120 min. An infusion of Intralipid and heparin was added during min 60-120. In one of two tests, the subjects ingested 250mg of Acipimox 60 min before the hyperglycemic clamp. A third test (also with Acipimox) was performed in seventeen of the diabetic subjects after three days of a low-fat diet. Acipimox lowered FA levels and enhanced insulin sensitivity in non-diabetic diabetic and diabetic subjects alike. Acipimox administration failed to affect insulin secretion rates in non-diabetic subjects and in the group of diabetic subjects as a whole. However, in the diabetic subjects Acipimox increased integrated insulin secretion rates during min 60-120 min in the 50% having the lowest levels of hemoglobin A1c (379 ± 34 with vs. 326 ± 30 pmol·kg-1·min-1 without Acipimox, P<0.05). A three day dietary intervention diminished energy from fat from 39 to 23% without affecting FA levels and without improving the insulin response during clamps. Elevated FA levels may tonically inhibit stimulated insulin secretion in a subset of type II diabetic subjects.

• Qvigstad, Elisabeth; Grill, Valdemar & Bjerve, Kristian S (2002). Effects of long-term fasting on insulin responses to fatty acids in man. Scandinavian Journal of Clinical and Laboratory Investigation.  ISSN 0036-5513.  62, s 271- 278 Vis sammendrag

  Objective: To investigate whether the prolonged physiological elevation of non-esterified fatty acids (NEFA) seen in man during fasting associates with an altered acute insulin response to NEFA. Subjects and methods: Fourteen non-diabetic subjects, age18-25 years, BMI 23,2 ± 0,8 kg/m2 underwent hyperglycemic clamps (blood glucose 11 mM) for 120 min. during which either saline or Intralipid was administered during the last 60 min. Subjects were tested after an overnight as well as after a 58h fast. Results: After the overnight fast insulin levels increased during Intralipid infusion, reaching at min 120 an increment of 33,0 ± 8,5 mU/ml vs. 9,5 ± 4,4 mU/ml during saline, p<0,05 for difference. Conversely, after the 58 h fast, Intralipid failed to promote a successive increase of insulin levels (increment during Intralipid at min 120: 0,5 ± 5,8 mU/ml versus -4,3 ± 2,5 mU/ml during saline, NS). Insulin sensitivity as assessed by the amount of infused glucose and its ratio to insulin was enhanced by Intralipid after an overnight fast but was decreased after a 58 h fast. Conclusion: Long term elevated NEFA during fasting associates with diminished beta cell responsiveness to an acute elevation of fatty acids in conjunction with negative effects on insulin sensitivity.

• Qvigstad, Elisabeth; Mostad, Ingrid Løvold; Bjerve, Kristian S & Grill, Valdemar (2002). Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects. American Journal of Physiology. Endocrinology and Metabolism.  ISSN 0193-1849.  284, s 129- 137

Se alle arbeider i Cristin

• Qvigstad, Elisabeth (2018). The diversity of gestational diabetes: A therapeutic challenge. European Journal of Endocrinology.  ISSN 0804-4643.  178(3), s C1- C5 . doi: 10.1530/EJE-18-0012
• Christensen, Jacob J.; Retterstøl, Kjetil; Godang, Kristin; Roland, Marie Cecilie; Qvigstad, Elisabeth; Bollerslev, Jens; Ueland, Thor; Henriksen, Tore & Holven, Kirsten B. (2017). LDL cholesterol in early pregnancy and offspring cardiovascular disease risk factors.
• Christensen, Jacob J.; Retterstøl, Kjetil; Godang, Kristin; Roland, Marie Cecilie Paasche; Qvigstad, Elisabeth; Bollerslev, Jens; Ueland, Thor; Henriksen, Tore & Holven, Kirsten Bjørklund (2016). LDL cholesterol in early pregnancy and offspring cardiovascular disease risk factors.
• Christensen, Jacob J.; Retterstøl, Kjetil; Godang, Kristin; Roland, Marie Cecilie Paasche; Qvigstad, Elisabeth; Bollerslev, Jens; Ueland, Thor; Henriksen, Tore & Holven, Kirsten Bjørklund (2016). LDL cholesterol in early pregnancy and offspring cardiovascular disease risk factors.
• Christensen, Jacob J.; Retterstøl, Kjetil; Godang, Kristin; Roland, Marie Cecilie Paasche; Qvigstad, Elisabeth; Bollerslev, Jens; Ueland, Thor; Henriksen, Tore & Holven, Kirsten Bjørklund (2016). Women with elevated LDL-C in early pregnancy have offspring with elevated LDL-C at 6-13 years of age.
• Christensen, Jacob J.; Retterstøl, Kjetil; Godang, Kristin; Roland, Marie Cecilie Paasche; Qvigstad, Elisabeth; Bollerslev, Jens; Ueland, Thor; Henriksen, Tore & Holven, Kirsten Bjørklund (2016). Women with elevated LDL-C in early pregnancy have offspring with elevated LDL-C at 6-13 years of age.
• Christensen, Jacob J.; Retterstøl, Kjetil; Godang, Kristin; Roland, Marie Cecilie Paasche; Qvigstad, Elisabeth; Bollerslev, Jens; Ueland, Thor; Henriksen, Tore & Holven, Kirsten Bjørklund (2016). Women with elevated LDL-C in early pregnancy have offspring with elevated LDL-C at 6-13 years of age.
• Christensen, Jacob J.; Retterstøl, Kjetil; Godang, Kristin; Roland, Marie Cecilie Paasche; Qvigstad, Elisabeth; Bollerslev, Jens; Ueland, Thor; Henriksen, Tore & Holven, Kirsten Bjørklund (2016). Women with elevated LDL-C in early pregnancy have offspring with elevated LDL-C at 6-13 years of age.
• Qvigstad, Elisabeth; Gulseth, Hanne Løvdal; Risstad, Hilde; le Roux, Carel W.; Berg, Tore Julsrud; Mala, Tom & Kristinsson, Jon Adalsteinn (2016). A novel technique of Roux-en-Y gastric bypass reversal for postprandial hyperinsulinemic hypoglycaemia: A case report. International Journal of Surgery Case Reports (IJSCR).  ISSN 2210-2612.  21, s 91- 94 . doi: 10.1016/j.ijscr.2016.02.033
• Qvigstad, Elisabeth; Voldner, Nanna; Bollerslev, Jens & Henriksen, Tore (2009). Diabetes i svangerskapet - forebygging over generasjoner. Tidsskrift for Den norske legeforening.  ISSN 0029-2001.  129(23), s 2494- 2496
• Buan, Bjørn; Grimsmo, Anders; Holmes, Peter; Nguyen, Man Hoang; Nilsen, Bjørn; Nystadnes, Torbjørn; Qvigstad, Elisabeth & Kvaase, Inger Elisabeth (red.) (2005). Nasjonale medisinske kvalitetsregistre. Forslag til fellesløsninger for registrene.
• Grill, Valdemar; Kollind, Magnus & Qvigstad, Elisabeth (2002). Nine weeks of bedtime diazoxide is well tolerated and beta cell beneficial in subjects with type 2 diabetes.
• Grill, Valdemar; Qvigstad, Elisabeth & Kollind, Magnus (2002). Nine weeks of bedtime diazoxide is well tolerated and beta cell beneficial in subjects with type 2 diabetes. Vis sammendrag

  Twenty-seven type 2 diabetic subjects (17M, 10F) using BTI and metformin participated. Half of the subjects received added treatment with Diazoxide, 100mg at bedtime, and half with placebo for 9 weeks. We registered no side effects of Diazoxide. Treatment with Diazoxide did not incur any increase in BTI. Plasma C-peptide responses to glucagon increased (0,15 ± 0,06nmol/l vs. -0,01 ± 0,04nmol/l for placebo, p<0,06 for difference). Plasma insulin levels were 66,2 ± 41,7pmol/l for Diazoxide vs. -84,2 ± 51,5, for placebo p<0,03. Bedtime Diazoxide decreased fasting glucagon levels by 41% vs. placebo, p<0,03. HbA1c levels did not change, whereas levels of blood glucose post breakfast were higher during Diazoxide (1,34 ± 0,43mmol/l, p<0,01 vs. placebo), but not at other time points. A breakfast test in the presence of repaglinide elicited a robust insulin response in Diazoxide treated subjects. Diazoxide taken at bedtime with BTI was well tolerated and produced beneficial effects on insulin and glucagon secretion, but failed to improve metabolic control.

• Qvigstad, Elisabeth; Grill, Valdemar & Kollind, Magnus (2002). Nine weeks of bedtime diazoxide is well tolerated and beta cell beneficial in subjects with type 2 diabetes. Vis sammendrag

  Twenty-seven type 2 diabetic subjects (17M, 10F) using BTI and metformin participated. Half of the subjects received added treatment with Diazoxide, 100mg at bedtime, and half with placebo for 9 weeks. We registered no side effects of Diazoxide. Treatment with Diazoxide did not incur any increase in BTI. Plasma C-peptide responses to glucagon increased (0,15 ± 0,06nmol/l vs. -0,01 ± 0,04nmol/l for placebo, p<0,06 for difference). Plasma insulin levels were 66,2 ± 41,7pmol/l for Diazoxide vs. -84,2 ± 51,5, for placebo p<0,03. Bedtime Diazoxide decreased fasting glucagon levels by 41% vs. placebo, p<0,03. HbA1c levels did not change, whereas levels of blood glucose post breakfast were higher during Diazoxide (1,34 ± 0,43mmol/l, p<0,01 vs. placebo), but not at other time points. A breakfast test in the presence of repaglinide elicited a robust insulin response in Diazoxide treated subjects. Diazoxide taken at bedtime with BTI was well tolerated and produced beneficial effects on insulin and glucagon secretion, but failed to improve metabolic control.

• Qvigstad, Elisabeth (2001). Effekter av frie fettsyrer på insulinfrigjøringen. Vis sammendrag

  En omdiskutert faktor for beta-cellesvikten ved type-2 diabetes er effekten av høye nivåer av sirkulerende frie fettsyrer, som er forhøyet under faste og ved type-2 diabetes. En langvarig forhøyelse av fettsyrer hemmer insulinfrigjøring o g insulinbio s yntese. Med denne bakgrunn, startet vi en studie med 21 type-2 diabetes pasienter med hypertriglyceridemi (>2.2 mmol/l) for å se om en akutt reduksjon av fettsyrer med acipimox vil bedre insulinfrigjøringen. Den akutte reduksjonen av fr ie fettsy rer på grunn av acipimox var assosiert med en noe bedret insulinfrigjøring og glukoseforbruk. Effekten var tydeligst hos de individene som hadde relativt god blodsukkerkontroll. 17 av forsøkspersonene deltok deretter i en kostholdsintervensj o n. Kos t ble registrert i 3 dager, deretter var det et intervall på 2-4 uker, deltakerne fikk så kostråd for å oppnå en redusert fettmengde, som de gjennomførte i 3 dager. Den kortvarige intervensjonen med fettredusert kost gav ingen økning i insul infrig jøri ng, men hadde en overraskende negativ effekt på insulinfølsomheten. Fettsyrene øker også betydelig ved faste. Vi undersøkte derfor om et økt fettsyrenivå forårsaket av langvarig faste ville virke negativt på insulinfrigjøringen. 14 fr iske personer gjennomførte både en 10t og en 58t faste, med etterfølgende tester. Langvarig faste hos ikke-diabetiske individer i hovedsak er assosiert med en negativ påvirkning av fettsyrer på glukose-stimulert insulinfrigjøring og også en parallell negativ virkning på insulinfølsomheten. Begge effektene kan være tilpasninger til redusert tilgang av føde og behov for å unngå hypoglykemi. Man kan tenke seg at disse effektene er utviklet som en fysiologisk respons og at de samme fettsyre-ef fekte ne trer i funksjon også ved type-2 diabetes - men da med et uhensiktsmessig resultat. Forandringer i fettsyrenivåene har betydning for insulinfrigjøringen hos mennesker. Dog er det foreløpig for tidlig å trekke linjen til klinisk anvendelse ved ty pe-2 diabetes.

• Mostad, Ingrid Løvold; Qvigstad, Elisabeth; Bjerve, Kristian S & Grill, Valdemar (2000). A low-fat diet for three days decreases insulin sensitivity in type-2 diabetes patients with hypertriglyceridemia.
• Qvigstad, Elisabeth & Grill, Valdemar (2000). Modulation by fatty acids of glucose-induced insulin secretion: diminished stimulatory effects after prolonged fasting.
• Qvigstad, Elisabeth & Grill, Valdemar (2000). Modulation by fatty acids of glucose-induced insulin secretion: diminished stimulatory effects after prolonged fasting.
• Qvigstad, Elisabeth; Mostad, Ingrid Løvold; Bjerve, Kristian S & Grill, Valdemar (1999). Acute reduction of fatty acids increases insulin secretion in type-2 diabetes.
• Qvigstad, Elisabeth; Mostad, Ingrid Løvold; Bjerve, Kristian S & Grill, Valdemar (1999). Lowering of fatty acids by acipimox improves insulin secretion in type-2 diabetes.
• Qvigstad, Elisabeth; Mostad, Ingrid Løvold; Bjerve, Kristian & Grill, Valdemar (1999). Akutt senking av fettsyrer øker insulinfrigjøringen ved type 2-diabetes.

Se alle arbeider i Cristin